Achieving pathological complete response (pCR) after NACT is a key indicator of favorable long-term outcomes, particularly in aggressive subtypes like triple-negative or human epidermal growth factor receptor 2 (HER2)-positive breast cancer [1–4]. The gene discussed is ERBB2; the disease is breast carcinoma.